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Abstract
This review of our literature describes the effects of many neuroleptic drugs on the sympathetic and hyperthermic
reactions due to orexin A, a neuropeptide affecting body temperature and food intake by an increase in sympathetic
activity. Haloperidol reduces, while clozapine and olanzapine block the hyperthermia induced by orexin A.
Risperidone enhances the elevation of body temperature due to orexin A. Quetiapine delays these hyperthermic
effects. The implications on human therapeutic strategies are discussed, including the involvement of orexinergic
pathway in the induction of obesity, induced by these neuroleptic substances. We summarize our published data in
a unique report so to emphasize the influences of these neuroleptic drugs on the control of body temperature,
exerted by orexinergic system. This large vision could be also useful to address therapeutic choices.
Patients with serious mental illness are at higher risk of developing metabolic abnormalities (e.g., weight gain,
increased blood pressure, and glucose or lipid levels) in comparison to general population. Since the risk increases
following initiation of narcoleptic therapy, it must assess carefully risks and benefits when choosing a particular
antipsychotic drug.
Keywords: Narcoleptic drugs; Orexin A; Sympathetic activity; Body
temperature; Body weight
Introduction
A neuropetide takes the name of orexin A since this peptide affects 
food intake [1-3]. Orexin A is synthesized by neurons located in the 
lateral and perifornical regions of the hypothalamus. Orexin neurons 
have extensive connections with the prefrontal cortex, limbic 
structures, hypothalamus, and brainstem, including areas involved in 
control of arousal, reward mechanisms, and autonomic control, and 
exert a primarily excitatory effect on neuronal activity via orexin 
receptors [4]. Orexin A does not influences only food intake, but this 
peptide also causes an enhancement of heart rate [5], blood pressure 
[6]. and metabolic rate [7,8]. These vegetative changes suggest that 
orexin A controls many autonomic functions. This peptide also exerts 
an influence on body temperature. When orexin A is injected 
intracerebroventricularly, there is an activation of the sympathetic 
firing rate of nerves to interscapular brown adipose tissue (IBAT). This 
activation is associated to an elevation of IBAT and colonic 
temperatures [5]. The contemporaneous tachycardia and 
hyperthermia after an icv injection of orexin A suggest a generalized 
stimulation of the sympathetic nervous system. Tonically active 
sympathetic premotor neurons in the rostral ventrolateral medulla 
project to the intermediolateral cell column of the spinal cord and 
provide an excitatory input to sympathetic preganglionic neurons so 
as to maintain the resting level of sympathetic vasomotor tone [9]. The 
rostral ventrolateral medulla is the key site for cardiovascular 
homoeostasis. Orexin A-immunoreactive neurons in the lateral
hypothalamus project to the rostral ventrolateral medulla. 
Microinjection of orexin A into the rostral ventrolateral medulla 
increases blood pressure and heart rate [10]. In the study by Tupone 
and colleagues, anatomical tracing and orexin immunehistochemical 
localization were combined with in vivo electrophysiological 
techniques to elucidate a central neural pathway through which orexin 
neurons influence IBAT thermogenesis and energy expenditure in 
rats. Viral retrograde tracing from IBAT and cholera toxin retrograde 
tracing from the rostral raphe pallidus indicated that a population of 
orexin neurons in the perifornical region of the lateral hypothalamus 
is synaptically connected to IBAT via a direct projection from the 
perifornical region of the lateral hypothalamus to the rostral raphe 
pallidus. The connection from the perifornical region of the lateral 
hypothalamus to neurons in the rostral raphe pallidus is important 
because the rostral raphe pallidus contains sympathetic premotor 
neurons whose excitatory drive to IBAT sympathetic preganglionic 
neurons in the thoracic spinal cord determines the sympathetic 
outflow to IBAT and, in turn, the level of IBAT metabolism and 
thermogenesis.
Furthermore, many cerebral areas expresses orexin receptors. This
indicates that orexin A controls various functions [11,12] including
regulation of sleep/wake cycle [13]. Neuroleptic drugs, as haloperidol,
clozapine, olanzapine, risperidone and quetiapine, can modify body
temperature, as showed by various experimental models [14-19]. In
the present mini-review, we summarize our published data in an
unique report so to emphasize the influences of these neuroleptic
drugs on the control of body temperature, exerted by orexinergic
system.
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Experimental Evidences
In this section, five our experiments are described in sequence. The 
sympathetic discharge of nerves to interscapular brown adipose tissue 
(IBAT), IBAT temperature and colonic temperature were registered in 
male Sprague-Dawley rats (anesthetized with urethane) before an 
intracerebroventricular administration of orexin A (1.5 nmol) and 
during a period of 180 min after this administration. The same 
variables were registered in rats with an intraperitoneal injection of 
one of these neuroleptic substance: haloperidol (1 mg/kg bw), 
clozapine (8 mg/kg bw), olanzapine (10 mg/kg bw), risperidone (50 
mg/kg bw), quetiapine (5 mg/kg bw). Haloperidol reduces the 
hyperthermia and sympathetic activation due to injection of orexin A. 
These effects are illustrated in the Figure 1-A. Clozapine and 
olanzapine block the increases in the sympathetic firing rate, IBAT and 
colonic temperatures induced by orexin A, as reported in the Figure 1-
B and 1-C. Risperidone enhances the effects of orexin A, as shown in 
the Figure 2-A while quetiapine delays the effects of the effects of 
orexin A on the sympathetic discharge, IBAT temperature and colonic 
temperature. These delayed effects are shown in the Figure 2-B.
Figure 1(A): Means ± S.E.M. of sympathetic firing rate of nerves to
interscapular brown adipose tissue (IBAT), IBAT and colonic
temperature in rats with injection of haloperidol plus orexin A
orsaline, with injection of clozapine plus orexin A or saline
Figure 1(B): Means ± S.E.M. of sympathetic firing rate of nerves to
interscapular brown adipose tissue (IBAT), IBAT and colonic
temperature in rats with injection of haloperidol plus orexin A
orsaline, with injection of olanzapine plus orexin A or saline
Figure 1(C): Means ± S.E.M. of sympathetic firing rate of nerves to 
interscapular brown adipose tissue (IBAT), IBAT and colonic 
temperature in rats with injection of haloperidol plus orexin A 
orsaline, The curve saline was not reported, because all values of this 
curve are very close to baseline values. The figure is reworkings 
(which does not infringe the copyrights) of the data already 
published
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Figure 2: Means ± S.E.M. of sympathetic firing rate of nerves to
interscapular brown adipose tissue (IBAT), IBAT and colonic
temperature in rats with injection of risperidone plus orexin A or
saline (A), with injection of quetiapine plus orexin A or saline (B).
The curve saline was not reported, because all values of this curve
are very close to baseline values. The figure is reworkings (which
does not infringe the copyrights) of the data already published
Detailed description of methodological procedure is reported in
papers cited in References list.
Discussion
Haloperidol reduces the sympathetic and thermogenic effects due
to an icv administration of orexin A [20,21]. Since the increase in the
sympathetic activity induced by orexin A is reduced by haloperidol
(antagonist of D2 receptors of the dopaminergic system), an
involvement of the D2 receptors can be hypothesized. This indicates
that an activation of dopaminergic system could be a possible
mechanism of sympathetic and thermogenic stimulation induced by
orexin A.
Figure 3 showing the effects exerted by neuroleptics on the
orexinergic activation, as reported in five our experiments, which have
been already published.
Figure 3: Effects exerted by neuroleptics on the orexinergic
activation
Since clozapine has high affinity for dopamine receptors [22], an
involvement of the dopaminergic system can be hypothesized in the
block of hyperthermia induced by orexin A [23]. On the other hand,
an involvement of serotoninergic pathways in the orexin-induced
hyperthermia cannot be excluded. Since clozapine is an antagonist of
5-HT2A, 5-HT2C, 5-HT6 and 5-HT7 receptors [24,25]. The blockade
of these receptors could determine the lack of the hyperthermia due to
orexin A.
Furthermore, several laboratories found an even higher affinity for
α1-adrenergic receptors [26,27]. Indeed, it was shown that central
blockade of α1-adrenergic receptors produces hypothermia [28], and
that α1-agonists block the hypothermic effects of clozapine [29]. Then,
the central blockade of α1-adrenergic receptors due to clozapine could
be responsible for the lack of the body temperature elevation caused by
orexin A. Clozapine blocks completely the hyperthermic action of
orexin A. This indicate that patients treated with clozapine are non
responsive to physiological variations of orexin A. This non-
responsiveness to orexin A could induce not only hypothermia, but
also body weight gain [30]. Indeed, orexin A is involved in the
activation of thermogenesis related to eating behaviour. The
thermogenesis due to food intake is an important factor in the
regulation of body weight and the lack of this thermogenesis causes
the obesity [31,32]. Moreover, the therapy of rare but dangerous
hypothermia caused by clozapine should exclude drugs, which affect
the orexinergic system to induce an elevation of body temperature.
Since olanzapine is an antagonist of 5-HT2 and D1-D2 receptors 
[33], the block of these receptors could cause the lack of body 
temperature elevation due to orexin A [34, 35]. Since olanzapine exerts 
also influences on cholinergic, adrenergic and histaminergic pathways, 
an involvement of these pathways cannot be excluded [36]. The 
therapy of the rare but dangerous hypothermia caused by olanzapine 
[37] cannot comprehend substances affecting the orexinergic system to 
elevate body temperature: this system is blocked by olanzapine. We can 
suppose that the body weight gain could be caused, at least in part, by a 
decrease in the thermogenic changes due to orexin A. Because weight 
gain due to antipsychotic drugs is a frequent reason for noncompliance 
with pharmacological treatment [38], studies on mechanisms affecting 
obesity are very important in the management of psychiatric therapy.
Although metabolic abnormalities are associated with almost all
second generation antipsychotics, clozapine and olanzapine appear to
be most consistently associated with the development of metabolic
symdrome. In the retrospective-prospective cohort comparison study
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[39], the difference between first generation antipsychotics and second
generation antipsychotics-treated patients disappeared when patients
on clozapine and olanzapine were removed from the analysis.
Olanzapine has also been associated with significant weight gain. In
the CATIE study, patients in the olanzapine group gained more weight
than with any other drug (mean weight gain was 0.9 kg monthly), and
30% of patients in the olanzapine group gained 7% or more of their
baseline body weight (compared with 7-16% in the other groups) [40].
Similarly, other studies have reported significant increase in body
weight, serum leptin levels, and percentage of body fat [41] and new
onset diabetes [42] in patients treated with olanzapine.
Risperidone is an atypical neuroleptic substance which is an
antagonist of 5-HT2 receptors. This antagonism is accompanied by a
milder antagonism of dopamine D2 receptors [43]. An administration
of risperidone potentiates hyperthermic reactions due to orexin A [44]
suggesting that these thermic effects involve serotoninergic and
dopaminergic pathways. This seems to demonstrate that a 5-HT2
receptor antagonism is higher than a D2 receptor antagonism in the
induction of the amplified hyperthermia caused by orexin A. Since
rare cases of strong fever have been described in the subjects treated
with risperidone, an involvement of orexinergic system in the fever
due to risperidone is plausible.
Quetiapine delays (but it does not reduce) the activation of the 
sympathetic discharge. Furthermore, hyperthermia is the same caused 
by the injection of orexin A alone [45]. Because quetiapine is an 
antagonist of 5-HT2c and (in rather weak manner) D2 receptors [46], 
the block of these receptors could cause the delayed elevation of the 
body temperature. Since quetiapine affects adrenergic and 
histaminergic pathways, these systems could be involved in delayed 
responses to injection of orexin A, [46,47]. Since quetiapine does not 
block the orexinergic system, drugs affecting orexinergic pathway 
could be utilized in the therapy of rare but dangerous hypothermia 
due to quetiapine.
The experiments described in this mini-review are based on
exogenously applied orexin A. No conclusion can be drawn on the
endogenus orexin system. For this reason, it is desirable that
researchers perform further experiments on how to investigate the
effect of the endogenously released orexin ligands in interaction with
neuroleptics.
Although we cannot conclude much from these experiments with 
regards to the endogenous orexin system and its role, these 
experiments demonstrate that an icv administration of orexin A causes 
an increase in temperature of IBAT, that is strongest effector of 
unrelated-shivering thermogenesis in the rat [48-50], showing that the 
increase in heat production is also caused by a stimulation of non-
shivering thermogenesis [48,51-53]. The sympathetic nervous system 
controls the IBAT activity and factors, which affect thermogenesis, 
exert an action centrally to induce modification of the sympathetic 
discharge to IBAT [54,45,55].
The described experiment indicates that orexin A affects body
temperature, independently of food intake. The name taken to orexin
A, named primarily hypocretin- 1 [56], was due to the hyperphagic
behavior after injection of this neuropeptide, assigning a principal role
in the eating behavior [57]. These results indicate that orexin A causes
high elevations of body temperature in anesthetized rats. Thus, this
hyperthermia is unrelated to eating behavior [53,59,60].
There are a variety of binding-sites linked with temperature
modulation (controlled by the autonomic nervous system) and
metabolic syndrome that are present. The autonomic nervous system
is involved in the control of eating behavior through influences exerted
on the production and loss of heat [1,61]. Thus, the control of body
temperature is strictly associated with the control of body weight; this
is in accord with the “thermoregulatory hypothesis” of food intake
[62]. On the other hand, the metabolic balance is controlled by the
autonomic nervous system, so that the vegetative influences affect the
storage and the consumption of energy. The consequences of this
hypothesis are that subjects with a high set-point of body temperature
and/or low sympathetic activity are induced to eat a high quantity of
food to elevate the sympathetic discharge and body temperature.
Conversely, subjects with a low thermal set-point and/or a high
sympathetic tone need to introduce a lower quantity of food to reach a
prefixed thermal set-point. On the other hand, alterations of
postprandial thermogenesis due to a reduced response of sympathetic
activation can play an important role in inducing obesity. In other
words, subjects with a low postprandial sympathetic activation need to
introduce a higher quantity of foot to reach a prefixed body
temperature. Patients with serious mental illness are at higher risk of
developing metabolic abnormalities (e.g., weight gain, increased blood
pressure, glucose or lipid levels) in comparison to general population.
Since the risk increases following initiation of neuroleptic therapy, it
must assess carefully risks and benefits when choosing a particular
antipsychotic drug [63].
In conclusion, this report emphasizes the influences of neuroleptic
drugs on the control of body temperature, exerted by orexinergic
system. This large vision (see summary scheme) could be also useful to
address therapeutic choices.
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